GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

electroCore, ECOR · USD

Health Care · US listing · 🇺🇸 United States

Compare

7.18

-0.97%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About electroCore,

From its filings with the US Securities and Exchange Commission

SEC filings

electroCore, is based in Rockaway, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ECOR. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2025, it reported revenue of $32.0m and a net loss of $14.0m. At that date it held total assets of $18.7m and shareholders' equity of −$1.7m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
22 Jun 2018
Employees
83
Head office
200 FORGE WAY, ROCKAWAY, NJ, 07866
Incorporated in
DE
Classification
Electromedical & Electrotherapeutic Apparatus
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Thomas ErricoIndependent Chairman of the Board$169,900
  • Mr. Daniel GoldbergerChief Executive Officer, Director, since 2019$1.6m
  • Mr. Joshua LevChief Financial Officer$703,822
  • Ms. Elena BonfiglioliDirector
  • Mr. James TheofilosDirector
  • Mr. John GandolfoIndependent Director$177,400
  • Ms. Julie GoldsteinIndependent Director$162,550
  • Mr. Thomas PattonIndependent Director$172,726
  • Ms. Patricia WilberIndependent Director$167,495

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
35
Environment
45
Social
30
Governance
29
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • electroCore offers the gammaCore device for non-invasive vagus nerve stimulation therapy.
  • The company targets adults suffering from episodic cluster and migraine pain.
  • GammaCore provides a simple-to-use hand-held non-drug treatment option for patients.

Weaknesses

  • The firm employs only 45 full-time staff members currently.
  • electroCore operates with a small workforce of 83 total employees.
  • The company relies on a single primary device for its therapy.

Opportunities

  • The firm aims to treat gastric motility disorders in patients.
  • electroCore seeks to address psychiatric and sleep disorders effectively.
  • The company targets respiratory fields for new non-invasive therapy applications.

Threats

  • The company faces competition in the neurology treatment market segment.
  • Regulatory hurdles may impact the approval of new therapy indications.
  • Market adoption of non-drug treatments remains uncertain for some patients.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.